Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
31
TLT.V Quote, Financials, Valuation and Earnings
Last price:
$0.29
Seasonality move
:
-8.88%
Day range:
$0.29 - $0.29
52-week range:
$0.15 - $0.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
74.62x
P/B ratio:
70.67x
Volume:
12.3K
Avg. volume:
116.2K
1-year change:
61.11%
Market cap:
$77.2M
Revenue:
$1M
EPS (TTM):
-$0.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TLT.V
Theralase Technologies, Inc.
|
$300K | -- | -26.9% | -- | $0.70 |
|
ARCH.V
Arch Biopartners, Inc.
|
-- | -- | -- | -- | -- |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
MBX.TO
Microbix Biosystems, Inc.
|
$4.6M | -- | -13.67% | -- | $0.50 |
|
RVX.TO
Resverlogix Corp.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TLT.V
Theralase Technologies, Inc.
|
$0.29 | $0.70 | $77.2M | -- | $0.00 | 0% | 74.62x |
|
ARCH.V
Arch Biopartners, Inc.
|
$0.6000 | -- | $40.8M | -- | $0.00 | 0% | -- |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MBX.TO
Microbix Biosystems, Inc.
|
$0.23 | $0.50 | $29.8M | 25.45x | $0.00 | 0% | 1.80x |
|
RVX.TO
Resverlogix Corp.
|
$0.11 | -- | $30.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TLT.V
Theralase Technologies, Inc.
|
22.64% | -0.884 | 0.65% | 0.05x |
|
ARCH.V
Arch Biopartners, Inc.
|
-272.64% | 2.282 | 3.22% | 0.00x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
MBX.TO
Microbix Biosystems, Inc.
|
20.51% | 1.461 | 21.51% | 4.27x |
|
RVX.TO
Resverlogix Corp.
|
-489.29% | -0.718 | 357.88% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TLT.V
Theralase Technologies, Inc.
|
$98.6K | -$1M | -238.89% | -283.94% | -364.81% | -$702.3K |
|
ARCH.V
Arch Biopartners, Inc.
|
-- | -$1.5M | -- | -- | -- | -$849.9K |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
MBX.TO
Microbix Biosystems, Inc.
|
$1.7M | -$949.2K | -12.16% | -14.86% | -22.5% | -$2.8M |
|
RVX.TO
Resverlogix Corp.
|
-$147.4K | -$1.6M | -- | -- | -- | -$1.3M |
Theralase Technologies, Inc. vs. Competitors
-
Which has Higher Returns TLT.V or ARCH.V?
Arch Biopartners, Inc. has a net margin of -361.91% compared to Theralase Technologies, Inc.'s net margin of --. Theralase Technologies, Inc.'s return on equity of -283.94% beat Arch Biopartners, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TLT.VTheralase Technologies, Inc.35.27% -$0.00 $1.4M ARCH.VArch Biopartners, Inc.-- -$0.02 -$965.8K -
What do Analysts Say About TLT.V or ARCH.V?
Theralase Technologies, Inc. has a consensus price target of $0.70, signalling upside risk potential of 141.38%. On the other hand Arch Biopartners, Inc. has an analysts' consensus of -- which suggests that it could grow by 483.33%. Given that Arch Biopartners, Inc. has higher upside potential than Theralase Technologies, Inc., analysts believe Arch Biopartners, Inc. is more attractive than Theralase Technologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLT.VTheralase Technologies, Inc.1 0 0 ARCH.VArch Biopartners, Inc.0 0 0 -
Is TLT.V or ARCH.V More Risky?
Theralase Technologies, Inc. has a beta of 0.525, which suggesting that the stock is 47.527% less volatile than S&P 500. In comparison Arch Biopartners, Inc. has a beta of 1.561, suggesting its more volatile than the S&P 500 by 56.076%.
-
Which is a Better Dividend Stock TLT.V or ARCH.V?
Theralase Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arch Biopartners, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theralase Technologies, Inc. pays -- of its earnings as a dividend. Arch Biopartners, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLT.V or ARCH.V?
Theralase Technologies, Inc. quarterly revenues are $279.6K, which are larger than Arch Biopartners, Inc. quarterly revenues of --. Theralase Technologies, Inc.'s net income of -$1M is higher than Arch Biopartners, Inc.'s net income of -$1.6M. Notably, Theralase Technologies, Inc.'s price-to-earnings ratio is -- while Arch Biopartners, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theralase Technologies, Inc. is 74.62x versus -- for Arch Biopartners, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLT.VTheralase Technologies, Inc.74.62x -- $279.6K -$1M ARCH.VArch Biopartners, Inc.-- -- -- -$1.6M
-
Which has Higher Returns TLT.V or COOL.CX?
Core One Labs, Inc. has a net margin of -361.91% compared to Theralase Technologies, Inc.'s net margin of --. Theralase Technologies, Inc.'s return on equity of -283.94% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TLT.VTheralase Technologies, Inc.35.27% -$0.00 $1.4M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About TLT.V or COOL.CX?
Theralase Technologies, Inc. has a consensus price target of $0.70, signalling upside risk potential of 141.38%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Theralase Technologies, Inc. has higher upside potential than Core One Labs, Inc., analysts believe Theralase Technologies, Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLT.VTheralase Technologies, Inc.1 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is TLT.V or COOL.CX More Risky?
Theralase Technologies, Inc. has a beta of 0.525, which suggesting that the stock is 47.527% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock TLT.V or COOL.CX?
Theralase Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theralase Technologies, Inc. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLT.V or COOL.CX?
Theralase Technologies, Inc. quarterly revenues are $279.6K, which are larger than Core One Labs, Inc. quarterly revenues of --. Theralase Technologies, Inc.'s net income of -$1M is higher than Core One Labs, Inc.'s net income of --. Notably, Theralase Technologies, Inc.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theralase Technologies, Inc. is 74.62x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLT.VTheralase Technologies, Inc.74.62x -- $279.6K -$1M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns TLT.V or CURE.X.CX?
Biocure Technology has a net margin of -361.91% compared to Theralase Technologies, Inc.'s net margin of --. Theralase Technologies, Inc.'s return on equity of -283.94% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TLT.VTheralase Technologies, Inc.35.27% -$0.00 $1.4M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About TLT.V or CURE.X.CX?
Theralase Technologies, Inc. has a consensus price target of $0.70, signalling upside risk potential of 141.38%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Theralase Technologies, Inc. has higher upside potential than Biocure Technology, analysts believe Theralase Technologies, Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings TLT.VTheralase Technologies, Inc.1 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is TLT.V or CURE.X.CX More Risky?
Theralase Technologies, Inc. has a beta of 0.525, which suggesting that the stock is 47.527% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TLT.V or CURE.X.CX?
Theralase Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theralase Technologies, Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLT.V or CURE.X.CX?
Theralase Technologies, Inc. quarterly revenues are $279.6K, which are larger than Biocure Technology quarterly revenues of --. Theralase Technologies, Inc.'s net income of -$1M is higher than Biocure Technology's net income of --. Notably, Theralase Technologies, Inc.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theralase Technologies, Inc. is 74.62x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLT.VTheralase Technologies, Inc.74.62x -- $279.6K -$1M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns TLT.V or MBX.TO?
Microbix Biosystems, Inc. has a net margin of -361.91% compared to Theralase Technologies, Inc.'s net margin of -27.67%. Theralase Technologies, Inc.'s return on equity of -283.94% beat Microbix Biosystems, Inc.'s return on equity of -14.86%.
Company Gross Margin Earnings Per Share Invested Capital TLT.VTheralase Technologies, Inc.35.27% -$0.00 $1.4M MBX.TOMicrobix Biosystems, Inc.41.09% -$0.01 $33.5M -
What do Analysts Say About TLT.V or MBX.TO?
Theralase Technologies, Inc. has a consensus price target of $0.70, signalling upside risk potential of 141.38%. On the other hand Microbix Biosystems, Inc. has an analysts' consensus of $0.50 which suggests that it could grow by 122.22%. Given that Theralase Technologies, Inc. has higher upside potential than Microbix Biosystems, Inc., analysts believe Theralase Technologies, Inc. is more attractive than Microbix Biosystems, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLT.VTheralase Technologies, Inc.1 0 0 MBX.TOMicrobix Biosystems, Inc.0 0 0 -
Is TLT.V or MBX.TO More Risky?
Theralase Technologies, Inc. has a beta of 0.525, which suggesting that the stock is 47.527% less volatile than S&P 500. In comparison Microbix Biosystems, Inc. has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.148%.
-
Which is a Better Dividend Stock TLT.V or MBX.TO?
Theralase Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Microbix Biosystems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theralase Technologies, Inc. pays -- of its earnings as a dividend. Microbix Biosystems, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLT.V or MBX.TO?
Theralase Technologies, Inc. quarterly revenues are $279.6K, which are smaller than Microbix Biosystems, Inc. quarterly revenues of $4.2M. Theralase Technologies, Inc.'s net income of -$1M is higher than Microbix Biosystems, Inc.'s net income of -$1.2M. Notably, Theralase Technologies, Inc.'s price-to-earnings ratio is -- while Microbix Biosystems, Inc.'s PE ratio is 25.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theralase Technologies, Inc. is 74.62x versus 1.80x for Microbix Biosystems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLT.VTheralase Technologies, Inc.74.62x -- $279.6K -$1M MBX.TOMicrobix Biosystems, Inc.1.80x 25.45x $4.2M -$1.2M
-
Which has Higher Returns TLT.V or RVX.TO?
Resverlogix Corp. has a net margin of -361.91% compared to Theralase Technologies, Inc.'s net margin of --. Theralase Technologies, Inc.'s return on equity of -283.94% beat Resverlogix Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TLT.VTheralase Technologies, Inc.35.27% -$0.00 $1.4M RVX.TOResverlogix Corp.-- -$0.00 -$21M -
What do Analysts Say About TLT.V or RVX.TO?
Theralase Technologies, Inc. has a consensus price target of $0.70, signalling upside risk potential of 141.38%. On the other hand Resverlogix Corp. has an analysts' consensus of -- which suggests that it could grow by 4661.91%. Given that Resverlogix Corp. has higher upside potential than Theralase Technologies, Inc., analysts believe Resverlogix Corp. is more attractive than Theralase Technologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLT.VTheralase Technologies, Inc.1 0 0 RVX.TOResverlogix Corp.0 0 0 -
Is TLT.V or RVX.TO More Risky?
Theralase Technologies, Inc. has a beta of 0.525, which suggesting that the stock is 47.527% less volatile than S&P 500. In comparison Resverlogix Corp. has a beta of 1.058, suggesting its more volatile than the S&P 500 by 5.792%.
-
Which is a Better Dividend Stock TLT.V or RVX.TO?
Theralase Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Resverlogix Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theralase Technologies, Inc. pays -- of its earnings as a dividend. Resverlogix Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLT.V or RVX.TO?
Theralase Technologies, Inc. quarterly revenues are $279.6K, which are larger than Resverlogix Corp. quarterly revenues of --. Theralase Technologies, Inc.'s net income of -$1M is higher than Resverlogix Corp.'s net income of -$1.3M. Notably, Theralase Technologies, Inc.'s price-to-earnings ratio is -- while Resverlogix Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theralase Technologies, Inc. is 74.62x versus -- for Resverlogix Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLT.VTheralase Technologies, Inc.74.62x -- $279.6K -$1M RVX.TOResverlogix Corp.-- -- -- -$1.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
